Study of LNF2007 for advanced solid tumors
Part of Cancer clinical trials.
This trial tests a new drug called LNF2007 that targets a specific protein (Claudin18.2) found on some advanced cancer cells. It aims to see if the drug is safe and can shrink tumors in people with stomach, pancreatic, or bile duct cancer that hasn't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must be generally able to do light activities (like walking or light chores).
- You must have advanced cancer of the stomach, pancreas, or bile ducts that has not responded to standard treatments or for which no standard treatment is available.
- A test of your tumor must show a protein called Claudin18.2 (a marker on some cancer cells).
- You must have measurable or evaluable tumor lesions (so doctors can track the response).
- Your organs (like kidneys, liver, and blood) must be functioning well enough to safely receive the trial drug.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental drug (LNF2105) for people with advanced solid tumors that have stopped responding to standard treatment. The drug targets a protein called Nectin-4 on cancer cells, and participating could give you access to a new option while helping to evaluate its safety.
This study tests an experimental drug (LNF1901) for people with advanced cancers that haven't responded to standard treatments. The goal is to see if it is safe and how well it works, and it might help control the cancer or shrink tumors.
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
This study is testing an experimental medication called GNC-077 that may help treat certain advanced cancers, especially those in the digestive system. The goal is to see if the drug is safe and how well it works in people who have already tried standard treatments.
This trial tests a new drug called PLB-002 for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug is safe and effective, especially for cancers that show a specific marker called CLDN6.
This trial tests a new drug called LCB02A, which targets a protein called Claudin 18.2 found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
Hear when a new Advanced Solid Tumors (Phase 1) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.